Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Expert Opinion on Drug Safety|January 22, 2013
Selective TNF-α inhibitor-induced injection site reactionsGiuseppe Murdaca, Francesca Spanò, Francesco PuppoOpen Access Rheumatology : Research and Reviews|May 7, 2013
Long-term treatment of rheumatoid arthritis with adalimumabGiuseppe Murdaca, Francesca Spanò, Francesco PuppoExpert Opinion on Drug Safety|July 30, 2013
Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritisGiuseppe Murdaca, Francesca Spanò, Francesco PuppoExpert Opinion on Drug Safety|January 7, 2014
Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safetyGiuseppe Murdaca, Francesca Spanò, Francesco PuppoRedox Report : Communications in Free Radical Research|May 17, 2013
Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitorsGiuseppe Murdaca, Francesca Spanò, Paola Cagnati, et al.Immunotherapy|April 26, 2014
Potential use of TNF-α inhibitors in systemic sclerosisGiuseppe Murdaca, Francesca Spanò, Miriam Contatore, et al.Drug Development Research|November 11, 2014
Pharmacogenetics and future therapeutic scenarios: what affects the prediction of response to treatment with etanercept?Giuseppe Murdaca, Rossella Gulli, Francesca Spanò, et al.Expert Opinion on Drug Metabolism & Toxicology|October 11, 2014
Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacyGiuseppe Murdaca, Francesca Spanò, Miriam Contatore, et al.Expert Opinion on Drug Safety|March 25, 2014
Efficacy and safety of etanercept in chronic immune-mediated diseaseGiuseppe Murdaca, Francesca Spanò, Miriam Contatore, et al.Expert Opinion on Drug Safety|October 21, 2011
Update upon efficacy and safety of TNF-α inhibitorsGiuseppe Murdaca, Barbara Maria Colombo, Paola Cagnati, et al.Pageof 3